ezabenlimab + BI 754111

**Ezabenlimab + BI 754111** is a combination of two investigational monoclonal antibodies developed for cancer immunotherapy. Ezabenlimab is an anti-PD-1 antibody that blocks programmed cell death protein-1 (PD-1) on T cells, preventing its interaction with PD-L1 and PD-L2 and thereby enhancing immune responses against tumors. BI 754111 is an anti-LAG-3 antibody that inhibits lymphocyte activation gene-3 (LAG-3), another immune checkpoint that limits T-cell activity. When used together, these antibodies block two separate inhibitory pathways on T cells. Preclinical and clinical studies show that their combination enhances interferon-γ secretion and antitumor activity more effectively than either antibody alone. This combination is being investigated for various advanced solid tumors, including colorectal, gastric, gastroesophageal junction, and esophageal cancers[1][3].

Other names

anti-PD-1 monoclonal antibody + anti-LAG-3 monoclonal antibody